Pharmaids Pharmaceuticals Intrinsic Value
PHARMAID Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| Book Value Method | asset | ₹31.43 | ₹28.29 - ₹34.57 | -33.8% | Book Value/Share: ₹15.71, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹27.43 | ₹24.69 - ₹30.17 | -42.3% | Revenue/Share: ₹13.71, P/S: 2.0x |
Want to compare with current market value? Check PHARMAID share price latest .
Valuation Comparison Chart
PHARMAID Intrinsic Value Analysis
What is the intrinsic value of PHARMAID?
Based on our comprehensive analysis using 2 different valuation methods, the estimated intrinsic value of Pharmaids Pharmaceuticals (PHARMAID) is ₹31.43 (median value). With the current market price of ₹47.50, this represents a -33.8% variance from our estimated fair value.
The valuation range spans from ₹27.43 to ₹31.43, indicating ₹27.43 - ₹31.43.
Is PHARMAID undervalued or overvalued?
Based on our multi-method analysis, Pharmaids Pharmaceuticals (PHARMAID) appears to be trading above calculated value by approximately 33.8%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.61 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 2.18 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | -21.8% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | -62.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.40x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Pharmaids Pharmaceuticals
Additional stock information and data for PHARMAID
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-14 Cr | ₹-20 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹-11 Cr | ₹-49 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹-4 Cr | ₹-7 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |